Keith Applegate, MD
Family Medicine · Lexington, KYNPI 1245235795
Payments from drug & device makers
Across 341 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$722
- Pfizer$525
- AbbVie$510
- AstraZeneca$506
- Novo Nordisk$438
- Amgen$425
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,21399%
- Education$341%
- Other$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $722 |
| Pfizer | 61 | $525 |
| AbbVie(2 entities) | 28 | $510 |
| AstraZeneca | 21 | $506 |
| Novo Nordisk | 24 | $438 |
| Amgen | 27 | $425 |
| GSK | 24 | $342 |
| Abbott | 14 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $162 |
| Boehringer Ingelheim | 6 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Merck | 6 | $90 |
| Gilead | 5 | $87 |
| Phathom Pharmaceuticals, Inc. | 5 | $85 |
| Exact Sciences | 5 | $80 |
| Johnson & Johnson | 6 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $72 |
| Astellas Pharma US Inc | 4 | $69 |
| Antares Pharma, Inc. | 1 | $64 |
| Dexcom, Inc. | 2 | $60 |
| Novartis | 4 | $59 |
| Verona Pharma, Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 3 | $46 |
| Welch Allyn | 1 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Atricure, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Nevro Corp. | 1 | $26 |
| Seqirus USA Inc | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Bayer | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Inogen, Inc. | 2 | $15 |
| Medtronic | 1 | $11 |
| Corium, LLC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,292 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $168,635 |
| JardianceEmpagliflozin | 90 | $129,077 |
| EliquisApixaban | 118 | $122,397 |
| MounjaroTirzepatide | 69 | $83,819 |
| XareltoRivaroxaban | 65 | $76,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $57,712 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $26,028 |
| FarxigaDapagliflozin Propanediol | 23 | $25,630 |
| TrulicityDulaglutide | 17 | $25,406 |
| JanuviaSitagliptin Phosphate | 16 | $22,346 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $20,179 |
| Spiriva RespimatTiotropium Bromide | 14 | $17,140 |
| EntrestoSacubitril/Valsartan | 17 | $13,445 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 52 | $11,574 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $11,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $438 | $168,635133 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $114 | $154,982115 claims |
| PfizerEliquis, Abrysvo | $525 | $132,637150 claims |
| Lilly USA, LLCMounjaro, Trulicity | $722 | $109,22586 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $342 | $94,417169 claims |
| Johnson & JohnsonXarelto | $77 | $76,69765 claims |
| MerckJanumet Xr, Januvia | $90 | $48,37334 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $506 | $43,68371 claims |
| NovartisEntresto | $59 | $13,44517 claims |
| AbbVieSynthroid | $510 | $4,433105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Lexington
- Barbara Fleming-PhillipsLexington$1.4M
- John RichardLexington$226K
- Eleida Tur OlivaLexington$113K
- Susan NeilLexington$18K
- Brian SmithVersailles$7.7M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.